Artivion (AORT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $95.8M, up 10% year-over-year in constant currency, with adjusted EBITDA rising 28% to $17.7M, driven by strong product portfolio and international expansion.

• Net loss narrowed to $2.3M, or $0.05 per share, while non-GAAP net income was $5.0M, or $0.12 per share.

• Regulatory milestones included BioGlue approval in China, first PMA module for AMDS submitted to FDA, and NEXUS TRIOMPHE trial enrollment completed.

• Operating expenses decreased 2% for the quarter, mainly due to lower business development expenses.

Financial highlights

• Q3 2024 revenue was $95.8M, up 10% year-over-year in constant currency; gross margin was 63.7%-64%.

• Adjusted EBITDA grew 28% to $17.7M, with margin improving by up to 280 basis points to 18.5%.

• Free cash flow for Q3 2024 was $7.8M; cash balance at $56.2M as of September 30, 2024.

• Net loss for the quarter was $2.3M, improved from $9.8M loss last year; adjusted net income was $5.0M.

• Operating income for the quarter was $4.4M, compared to a loss of $1.2M last year.

Outlook and guidance

• Full-year 2024 constant currency revenue growth expected at 10–12%, with guidance narrowed to $389–$396M.

• Adjusted EBITDA for 2024 projected at $69–$72M, up 28–34% year-over-year, with 280 basis points of margin expansion.

• Free cash flow positive for FY24 expected; net debt leverage targeted at ~3.5x.

• 2025 guidance to be provided in February; no significant AMDS revenue expected in 2025 due to launch timing.

• Cash from operations and existing cash expected to meet operational liquidity needs for at least the next twelve months.